Introducing Revvity – Expanding the boundaries of human potential through science. All products and services previously affiliated with Oxford Immunotec are now part of Revvity.
Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American ThoracicSociety/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. Published online December 8, 2016:ciw694. doi:10.1093/cid/ciw694
Wong SH, Gao Q, Tsoi KKF, et al. Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax. 2016;71:64–72.
Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, IGRA Expert Committee, Centers for Disease Control and Prevention (CDC). Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection – United States, 2010. MMWR Recomm Rep. 2010; 59(RR-5:1-25.
WHO End TB Strategy. World Health Organization. Published September 8, 2015. Accessed November 12, 2020.
Wrighton-Smith P, Sneed L, Humphrey F, Tao X, Bernacki E. Screening health care workers with interferon-γ release assay versus tuberculin skin test: Impact on costs and adherence to testing (the SWITCH study). J Occupational & Environmental Med. 2012;54(7):806-815
GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology & Hepatology. 2020;5(1):17-30
Lai CC, Tan CK, et al. Diagnostic performance of whole-blood interferon-γ assay and enzyme-linked immunospot assay for active tuberculosis. J Microbiol Immunol Infect. 2011 Oct;44(5):406-7. doi: 10.1016/j.jmii.2011.07.002. Epub 2011 Sep 8.
Redelman-Sidi G, Sepkowitz KA. Interferon-gamma release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med 2013; 188:422-431. 2012/12/25. DOI: 10.1164/rccm.201209-1621CI.
Signs & Symptoms. Centers for Disease Control and Prevention. CDC Tuberculosis Signs and Symptoms. Published March 17, 2016. Accessed January 8, 2020.
Exposure to TB. Centers for Disease Control and Prevention. CDC Exposure to TB. Published March 21, 2016. Accessed January 8, 2020.
TB Risk Factors. Centers for Disease Control and Prevention. CDC TB Risk Factors. Published March 18, 2016. Accessed January 8, 2020.
Huebner R, Schein M, Bass J. The tuberculin skin test. Clin Infect Dis. 1993;968-975.
Treatment for TB Disease. Centers for Disease Control and Prevention. CDC Treatment for TB Disease. Published April 5, 2016. Accessed January 8, 2020.
This site uses cookies to store information on your computer. We use necessary cookies that are essential to make our site work; and non-necessary cookies that help us improve the user experience. ENABLE/DISABLE COOKIESACCEPTLEARN MORE
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.